Javelin Pharmaceuticals Receives Marketing Authorization Approval For Dyloject(R) In The United Kingdom

Javelin Pharmaceuticals, Inc. (Amex: JAV) announced that it has received marketing authorization approval in the United Kingdom for Dyloject(R), Javelin’s proprietary injectable formulation of diclofenac sodium (75 mg/2ml). “Dyloject’s UK approval is a milestone in establishing Javelin as a commercial provider of novel solutions for acute pain management,” stated Dr. Daniel B. Carr, Javelin’s CEO and CMO. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on November 7th, 2007